Regeneron’s Oncology Strategy Gets Warmer With Early Prostate Data

Company Posts Solid Q2 Sales Despite REGEN-COV Drop

 
• By Alaric DeArment
  
Regeneron reported its Q2 earnings and early data from a bispecific antibody trial • Source: Shutterstock

More from Earnings

More from Business